Glycemic Outcomes and Safety With Minimed 780G System in Children With Type 1 Diabetes Aged 2-6 Years
NCT ID: NCT04949022
Last Updated: 2022-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
38 participants
INTERVENTIONAL
2021-08-23
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Additionally, the study evaluates the perceived burden of the diabetes treatment to families during the advanced hybrid-closed loop system treatment (diabetes distress).
This is a prospective, non-randomized, single-arm study, where primary endpoint is the change in TIR after hybrid-closed loop system initiation. Secondary endpoints are safety (number of severe hypoglycaemias and diabetic ketoacidosis, DKA), HbA1c, time below range (TBR), mean sensor glucose (SG), standard deviation of SG, and coefficient of variation (CV).
The inclusion criteria are 1) TDD (total insulin daily dose) ≥ 8 units, 2) HbA1c \< 10%, 3) capability to use pump and the CGM, and 4) time from diabetes diagnosis more than 6 months. The exclusion criteria are hemophilia or any other bleeding disorder, a condition, which in the opinion of the investigator would put the participant at risk during the trial.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Evaluation of MiniMed™ 780G System With DS5 CGM in Children
NCT06604871
Analysis of Glycemic Control in Type 1 Diabetes Patients Using Hybrid Closed Loop Insulin Pump Therapy (Medtronic 670G)
NCT04051632
Evaluation of the MiniMed 780 System in Paediatric Subjects
NCT05574062
The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France.
NCT04308291
Comparison of Two Management Systems in Patients With Type 1 Diabetes (Pediatric SmartHome)
NCT03815487
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The treatment of small children's type 1 diabetes (T1D) is challenging. There is often great day-to-day and within-day variability in glucose levels and HbA1c targets are hard to achieve. The results on hybrid closed loop systems (HCL) in children have been encouraging, suggesting that an algorithm, which automatically doses basal insulin based on sensor glucose (SG) levels, improves time in range (TIR) (3.9-10 mmol/l / 71-180 mg/dl) and reduces the time spent below range (TBR). Despite of these improvements, the target level of TIR (70%) has not been reached in these studies.
In pivotal studies, Minimed 780G advanced HCL system has helped children over 7 years old to reach higher TIR and improve mealtime glycaemia without increasing TBR, severe hypoglycaemias or ketoacidosis.
This study evaluates the effectiveness to glycemic control and safety of advanced hybrid-closed loop system, Minimed 780G, in children aged between 2.0-6.99 years, with type 1 diabetes.
The study protocol is explained to the participants (2.0-6.99 year-old children) orally. Informed consent from participants' caregivers and those participants who can write will be taken by investigators, clinicians or diabetes nurses. The investigator will explain the nature of the study to the subject, and answer all questions regarding this study. Prior to any study-related screening procedures being performed on the participant, the informed consent statement will be reviewed and signed and dated by participant's caregiver.
STUDY PROTOCOL
The study includes a two week run-in-phase in open loop Manual mode, which equals for standard sensor augmented pump (SAP) treatment (this feature is also in the same device), which is followed by a three month study phase with advanced hybrid closed loop Auto mode.
The participants will be given an advanced HCL pump (MiniMed 780G™ system with SmartGuard Medtronic, Northridge, CA). Minimed 780g™ is an insulin pump, which doses insulin automatically to patients subcutaneous tissue every 5 minutes based on SG values. The maximal dosing is based on participants TDD. The SmartGuard feature uses meal information, up to date SG reading, and SG target values to control basal insulin delivery. Additionally, it can automatically deliver a correction bolus to correct a high SG reading. The MiniMed 780G insulin pump requires a minimum of eight units and a maximum of 250 units per day to operate using the SmartGuard feature (Medtronic Minimed 780g™ system user guide).
This device has CE mark and is indicated to children aged over 7 years who require insulin over 8 units/day. In manufacturers safety studies, no adverse effects (diabetic ketoacidosis (DKA) or severe hypoglycaemias) has been reported in children over 7 years old who had TDD over 8 units/day (MDT personal communication).
The infusion set of insulin pump is changed every 2-3 days by patients' caregivers. The material connected to subcutaneous tissue is Teflon. The SG values are measured by continuous glucose monitor (CGM). The used CGM is Guardian3 sensor, which is integrated to Minimed 780g™ system. It measures the glucose level in the subcutaneous tissue. The CGM sensor connects to a transmitter that sends the glucose data to insulin pump. The sensor is worn for 7 days and then replaced with a new one by the participants' caregivers.
The traceability is achieved by each device's serial number (insulin pump, CGM transmitter). The glucose sensors, infusion sets, reservoirs and glucose sensors have lot numbers.
The families are trained to use the device by Medtronic's local representatives (technical issues), diabetes nurses, and clinicians (dosing and other medical issues). If the family has been on a sensor augmented pump (SAP) treatment previously, training includes one 3 hour session, a normal procedure in our clinic, at the outpatient clinic. If family has no previous experience on pump treatment or CGM, they will first try CGM out for 2 weeks and then 3-days visit on day hospital is arranged to first learn the basics on insulin pump treatment.
POWER ANALYSES
Based on previous studies, it was estimated that a significant difference in increased TIR between the advanced HCL treatment and the Manual mode would be 10% and the standard deviation is expected to be 13%. Taken these into account, the power of 90% to detect a difference between the modes with type 1 error rate of 0.05, 35 participants should complete the protocol. The dropout rate is estimated to be less than 3%, thus 38 HCL systems have been reserved for 38 participants.
ETHICAL ISSUES
This study is conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki. This study will be conducted in accordance with Good Clinical Practice (GCP), as defined by the International Conference on Harmonization (ICH) and in accordance with the ethical principles underlying European Union Directive 2001/20/EC and 2005/28/EC (or Regulation (EU) No 536/2014). The ethics committee of Helsinki University Hospital and The Finnish Medicines Agency has approved the study protocol.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hybrid closed loop system
Initiation of 780G insulin pump. First two weeks run-in-phase in open loop Manual mode, followed by a12 month study phase with advanced hybrid closed loop Auto mode.
Medronic 780G insulin pump
Commercial hybrid closed loop system Medronic 780G
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Medronic 780G insulin pump
Commercial hybrid closed loop system Medronic 780G
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c \< 10%
* capability to use pump and the CGM
* time from diabetes diagnosis more than 6 months
Exclusion Criteria
2 Years
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic International Trading Sarl
INDUSTRY
Helsinki University Central Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tero Varimo, MD, PhD
MD, PhD, fellow in pediatric endocrinology, principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna-Kaisa Tuomaala, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Helsinki University Hospital, New Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helsinki University Hospital, New Children's Hospital and Jorvi Hospital
Helsinki, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015 Jun;38(6):971-8. doi: 10.2337/dc15-0078.
Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, Weinzimer SA, DeBoer MD, Buckingham BA, Chernavvsky D, Wadwa RP; iDCL Trial Research Group. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. N Engl J Med. 2020 Aug 27;383(9):836-845. doi: 10.1056/NEJMoa2004736.
Lind M, Pivodic A, Svensson AM, Olafsdottir AF, Wedel H, Ludvigsson J. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ. 2019 Aug 28;366:l4894. doi: 10.1136/bmj.l4894.
Hagger V, Hendrieckx C, Sturt J, Skinner TC, Speight J. Diabetes Distress Among Adolescents with Type 1 Diabetes: a Systematic Review. Curr Diab Rep. 2016 Jan;16(1):9. doi: 10.1007/s11892-015-0694-2.
Pulkkinen MA, Varimo TJ, Hakonen ET, Harsunen MH, Hyvonen ME, Janer JN, Kiiveri SM, Laakkonen HM, Laakso SM, Wehkalampi K, Hero MT, Miettinen PJ, Tuomaala AK. MiniMed 780G in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks. Diabetes Technol Ther. 2023 Feb;25(2):100-107. doi: 10.1089/dia.2022.0313. Epub 2022 Dec 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ERP-2020-12544
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.